pertuzumab
Roche Highlights Inavolisib Market Prospects as Q1 Revenues Fall 6 Percent on Currency Headwinds
Premium
The Swiss drugmaker expects a decision from the FDA on inavolisib as a treatment for PIK3CA-mutated breast cancer by the end of the year.
The firm expects the FDA to approve its PI3Kα inhibitor inavolisib by the end of 2024 as it invests in additional clinical trials across its breast cancer portfolio.
Bolt Biotherapeutics Studying BDC-1001 With Genentech's Perjeta in HER2-Positive Breast Cancer
The company is pairing its immune-stimulating antibody conjugate with the monoclonal antibody Perjeta after the combo showed synergistic activity in preclinical research.
The company said during a Q3 earnings call that it expects the ALK inhibitor to add $500 million in sales a year if it's approved in early-line ALK-positive NSCLC.
In the first half of 2023, the Swiss biotech reported growth in sales of several precision oncology medicines including its HER2-targeted and immunotherapy products.